Therapeutic advances in BIG3‐PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|5|550-558

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.5, 2015-05, pp. : 550-558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ginkgetin inhibits the growth of DU−145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity

By  

Cancer Science, Vol. 106, Iss. 4, 2015-04 ,pp. : 413-420

John Wiley & Sons Inc

Access to resources Recommend Favorite

Persistent activation of STAT3 by PIM2‐driven positive feedback loop for epithelial‐mesenchymal transition in breast cancer

By  

Cancer Science, Vol. 106, Iss. 6, 2015-06 ,pp. : 718-725

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects

By  

Cancer Science, Vol. 106, Iss. 4, 2015-04 ,pp. : 337-343

John Wiley & Sons Inc

Access to resources Recommend Favorite

Logical design of an anti‐cancer agent targeting the plant homeodomain in Pygopus2

By  

Cancer Science, Vol. 107, Iss. 9, 2016-09 ,pp. : 1321-1328

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance

By  

Cancer Science, Vol. 109, Iss. 1, 2018-01 ,pp. : 94-102

John Wiley & Sons Inc

Access to resources Recommend Favorite